Abstract: Disclosed are a fully human broad-spectrum neutralizing antibody against coronavirus, and the use thereof. Specifically disclosed are a fully human monoclonal antibody against an S2 region of coronavirus S protein, a nucleic acid sequence encoding the antibody, and a preparation method therefor. The antibody can effectively bind to and neutralize a variety of coronaviruses in a broad spectrum manner, and can be used for preventing and treating diseases related to coronavirus infection, such as SARS-CoV-2. Further disclosed is the potential use thereof in vaccine design.

Abstract: Provided is the use of an ECM1 gene-knockout mouse in the screening of an anti-hepatic fibrosis drug. Specifically, provided is a method for preparing an animal model of hepatic fibrosis or related diseases thereof in non-human mammals, which method comprises the following steps: (a) providing a non-human mammalian cell and inactivating an ECM1 gene in the cell, thereby obtaining a non-human mammalian cell in which the ECM1 gene is inactivated; and (b) using the cell in which the ECM1 gene is inactivated obtained in step (a) to prepare an animal model of hepatic fibrosis or related diseases thereof in which the ECM1 gene is inactivated. The animal model is an effective animal model of hepatic fibrosis or related diseases thereof, may be used for studying hepatic fibrosis or related diseases thereof, and may be used in the screening and testing of a particular drug.

Abstract: Provided is application of ECM1 in the prevention and/or treatment of liver fibrosis-related diseases, specifically provided is the use of ECM1 gene, or protein or a promoter thereof for preparing a composition or a formulation, the composition or formulation being used for (a) preventing and/or treating of liver fibrosis-related diseases; and/or for (b) maintaining liver homeostasis. The ECM1 gene, or the protein or promoter thereof can significantly (i) prevent and/or treat cirrhosis-related diseases; and/or (ii) maintain the liver homeostasis. In addition, the ECM1 gene, or the protein or promoter thereof can also significantly (i) inhibit the occurrence of liver fibrosis-related diseases; and/or (ii) inhibit the activation of hepatic stellate cells (HSCs).

Abstract: Provided herein is a human monoclonal antibody 8D6 against hepatitis C virus (HCV) infection. The antibody binds to the E2 subunit of HCV capsid protein, and can prevent HCV from infecting susceptible host cells. By using the antibody variable region gene or the complementary determining region (CDR) gene, different forms of genetic engineering antibodies have been transformed and produced in any expression system of the prokaryotic and eukaryotic cells as therapeutics to prevent or treat HCV infection.

Abstract: Provided herein is a human monoclonal antibody 8D6 against hepatitis C virus (HCV) infection. The antibody binds to the E2 subunit of HCV capsid protein, and can prevent HCV from infecting susceptible host cells. By using the antibody variable region gene or the complementary determining region (CDR) gene, different forms of genetic engineering antibodies have been transformed and produced in any expression system of the prokaryotic and eukaryotic cells as therapeutics to prevent or treat HCV infection.